Autosomal Dominant Hypocalcemia clinical trials at UCSF

2 in progress, 1 open to eligible people

Autosomal dominant hypocalcemia leads to low calcium levels due to genetic factors. UCSF is exploring the use of encaleret to see if it is safer and more effective than standard care. These trials are important for learning more about treating this condition.

Showing trials for

  • Encaleret Compared to Standard of Care in Participants With ADH1

    open to eligible people ages 16 years and up

    The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).

    Oakland, California and other locations

  • ADH1 and ADH2 Disease Monitoring Study (DMS)

    Sorry, in progress, not accepting new patients

    A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease presentation and progression through retrospective (past) and longitudinal prospective (over time into the future) data collection.

    Oakland, California and other locations

Last updated: